EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives

Pernille Y Ø Nielsen, Justyna Okarmus, Morten Meyer iD

Cells · 2023

DOI: 10.3390/cells12040651 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Pernille Y Ø Nielsen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Danish Parkinson Foundation, Faculty of Health Sciences at the University of Southern Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a neurodegenerative disorder that has been associated with mitochondrial dysfunction, oxidative stress, and defects in mitophagy as well as α-synuclein-positive inclusions, termed Lewy bodies (LBs), which are a common pathological hallmark in PD. Mitophagy is a process that maintains cellular health by eliminating dysfunctional mitochondria, and it is triggered by ubiquitination of mitochondrial-associated proteins—e.g., through the PINK1/Parkin pathway—which results in engulfment by the autophagosome and degradation in lysosomes. Deubiquitinating enzymes (DUBs) can regulate this process at several levels by deubiquitinating mitochondrial substrates and other targets in the mitophagic pathway, such as Parkin. Moreover, DUBs can affect α-synuclein aggregation through regulation of degradative pathways, deubiquitination of α-synuclein itself, and/or via co-localization with α-synuclein in inclusions. DUBs with a known association to PD are described in this paper, along with their function. Of interest, DUBs could be useful as novel therapeutic targets against PD through regulation of PD-associated defects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansalpha-SynucleinUbiquitin-Protein LigasesUbiquitinationDeubiquitinating Enzymes

Stichwörter der Autor:innen

Lewy bodiesPARK2mitochondriamitophagyneurodegenerationparkinprotein degradationubiquitin proteasome systemα-synuclein

Substanzen

alpha-SynucleinUbiquitin-Protein LigasesDeubiquitinating Enzymes

Autor:innen und Institutionen

  • Department of Neurobiology Research, Institute of Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark.
  • Department of Neurology, Odense University Hospital, 5000 Odense, Denmark.
  • BRIDGE-Brain Research Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark.

ORCID-Profile: Morten Meyer

Förderung

  • The Danish Parkinson Foundation
  • Faculty of Health Sciences at the University of Southern Denmark

Zitieren

APA

Nielsen, P. Y. Ø., Okarmus, J., & Meyer, M. (2023). Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives. Cells. https://doi.org/10.3390/cells12040651

Vancouver

Nielsen PYØ, Okarmus J, Meyer M. Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives. Cells. 2023. doi:10.3390/cells12040651

BibTeX
@article{Nielsen2023,
  author = {Nielsen, Pernille Y Ø and Okarmus, Justyna and Meyer, Morten},
  title = {Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12040651}
}
Kostenlos starten →